CD38 and tuberculosis: Although no differences in the T cell activation markers were observed at baseline for the patients included in groups 1 and 2, higher CD3+/HLA-DR+ and CD38+/CD8+ T cell activation profiles were observed for group 1 after HAART initiation, followed by a slight reduction of these immune activation markers along the HIV-TB treatment for group 1.